Literature DB >> 14715451

Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved?

Andréa C Paula-Lima1, Paulo Roberto Louzada, Fernando G De Mello, Sérgio T Ferreira.   

Abstract

The beta-amyloid peptide (Abeta) is centrally related to the pathogenesis of Alzheimer's disease (AD). Previous studies have suggested that the neurotoxicity of Abeta may be related to the overactivation of glutamatergic transmission and excitotoxicity, and that blockade of glutamate receptors prevents Abeta-induced cell death. Here, we show that melatonin, a pineal hormone, protects chick retinal neurons in culture against the neurotoxicity of Abeta and glutamate. Right-angle light scattering and thioflavin T fluorescence measurements, as well as light microscopy analysis, indicated that, under our experimental conditions, melatonin had no effect on the aggregation of Abeta. Interestingly, the neuroprotective action of melatonin against the toxicity of Abeta was significantly decreased in the presence of picrotoxin, an antagonist of GABA(A)-like receptors. By itself, picrotoxin had no effect. These results suggest that the neuroprotective effects of melatonin against Abeta neurotoxicity could be at least in part related to a decrease in the excitatory tonus, mediated by activation of GABA receptors and the resulting hyper-polarization of the neurons. Thus, selective pharmacological manipulation of neuronal excitatory/inhibitory tonus could be a potentially interesting new approach in the treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14715451     DOI: 10.1007/bf03033152

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  13 in total

1.  Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo.

Authors:  A Espinar; A García-Oliva; E M Isorna; A Quesada; F A Prada; J M Guerrero
Journal:  J Pineal Res       Date:  2000-03       Impact factor: 13.007

2.  Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide.

Authors:  A Westlind-Danielsson; G Arnerup
Journal:  Biochemistry       Date:  2001-12-11       Impact factor: 3.162

3.  Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS.

Authors:  L Niles
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 4.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

5.  Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum.

Authors:  C C Tenn; L P Niles
Journal:  Neuropharmacology       Date:  1997 Nov-Dec       Impact factor: 5.250

6.  Inhibition of Alzheimer beta-fibrillogenesis by melatonin.

Authors:  M Pappolla; P Bozner; C Soto; H Shao; N K Robakis; M Zagorski; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

7.  Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.

Authors:  B J Blanchard; G Konopka; M Russell; V M Ingram
Journal:  Brain Res       Date:  1997-11-21       Impact factor: 3.252

8.  Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism.

Authors:  C C Tenn; L P Niles
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

9.  The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors.

Authors:  Miguel A Pappolla; Marcia J Simovich; Tara Bryant-Thomas; Yau-Jan Chyan; Burkhard Poeggeler; Margarita Dubocovich; Roger Bick; George Perry; Felix Cruz-Sanchez; Mark A Smith
Journal:  J Pineal Res       Date:  2002-04       Impact factor: 13.007

10.  Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice.

Authors:  D X Tan; L C Manchester; R J Reiter; W Qi; S J Kim; G H El-Sokkary
Journal:  J Neurosci Res       Date:  1998-11-01       Impact factor: 4.164

View more
  11 in total

Review 1.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Amyloid-β decreases nitric oxide production in cultured retinal neurons: a possible mechanism for synaptic dysfunction in Alzheimer's disease?

Authors:  Leandro T Oliveira; Paulo Roberto Louzada; Fernando G de Mello; Sérgio T Ferreira
Journal:  Neurochem Res       Date:  2010-10-10       Impact factor: 3.996

4.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 5.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Neuroprotective properties of Valeriana officinalis extracts.

Authors:  João O Malva; Sandra Santos; Tice Macedo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 7.  GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.

Authors:  Mauricio O Nava-Mesa; Lydia Jiménez-Díaz; Javier Yajeya; Juan D Navarro-Lopez
Journal:  Front Cell Neurosci       Date:  2014-06-25       Impact factor: 5.505

Review 8.  Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.

Authors:  Karan Govindpani; Beatriz Calvo-Flores Guzmán; Chitra Vinnakota; Henry J Waldvogel; Richard L Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2017-08-21       Impact factor: 5.923

Review 9.  Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. a review.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

10.  A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.

Authors:  Karen M Barlow; Brian L Brooks; Frank P MacMaster; Adam Kirton; Trevor Seeger; Michael Esser; Susan Crawford; Alberto Nettel-Aguirre; Roger Zemek; Mikrogianakis Angelo; Valerie Kirk; Carolyn A Emery; David Johnson; Michael D Hill; Jeff Buchhalter; Brenda Turley; Lawrence Richer; Robert Platt; Jamie Hutchison; Deborah Dewey
Journal:  Trials       Date:  2014-07-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.